Lilly joins Novo in cardiovascular space after FDA nod for GLP-1/GIP agonist Mounjaro

With the approval, Eli Lilly’s Mounjaro becomes the first dual GIP/GLP-1 receptor agonist indicated to lower the risk of heart attack, stroke or cardiovascular death in adults with type 2 diabetes.